PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence.

CA is prevalent in PCa and arises predominantly by centriole overduplication as opposed to cell doubling events. Loss of centrioles is cellular stress that can promote senescence and suggests that PLK4 inhibition may be a viable therapeutic strategy in PCa.